We all face life threatening conditions, if we lose the key property of vasculature - the endothelial barrier. Faron has identified several molecular mechanisms involved in the control of endothelial functions, providing opportunities to develop new unique drugs for true unmet medical need.Read on ›
Faron's lead drug platform Traumakine prevents vascular leakage through the injured endothelium of several central organs, potentially saving lives of seriously ill patients, e.g. those having acute respiratory distress syndrome (ARDS). The Clevegen project aims at recovering tumour immunity to help the host fight tumour growth and spread by controlling one of the key regulatory pathways connected to several cancers.Read on ›
Faron sources innovations from Academia and has built a strong expert network to execute drug development programs. The key opinion leaders play a crucial role in every step of our work, from inventions to clinical protocols and dissemination of results.Read on ›
Faron wants to create shareholder value, not only by advancing the pipeline but also by optimizing commercial steps of Faron products in various territories. Faron has already limited territorial licenses but retains all rights in Europe and USA for all proprietary drug candidates under development.Read on ›
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. Faron is based in Turku, Finland. Faron is listed on AIM under the ticker ‘FARN’.
Faron has entered into pan-European pivotal Phase III study with its lead candidate Traumakine®, which targets the treatment of Acute Respiratory Distress Syndrome (ARDS). This study, called INTEREST, aims to achieve conditional European approval and has received €6 million European Union Framework Programme funding (FP7). Currently there is no available drug treatment for ARDS, an orphan lung disease which has a high 30–45% mortality rate.
Find out the Traumakine® mechanism of action, presented by Professor Geoff Bellingan, medical director at University College London Hospitals (UCLH), who led the Phase II trial.